The excerpt below comes from our recent full-length interview with Brian Pereira, CEO of Visterra Inc. We sit with Brian as he shares how Visterra is using a proprietary platform to engineer new antibodies to combat influenza and other infectious diseases, and where he sees the future of this exciting company. (Full disclosure: my venture firm Lux Capital is an equity investor in Visterra).
Pandemics and Panaceas: Why an MIT Inventor Chased The World's Most Dangerous Flu
Forbes - 29 Dec 2013 19:21
The excerpt below comes from our recent full-length interview with Brian Pereira, CEO of Visterra Inc. We sit with Brian as he shares how Visterra is using a proprietary platform to engineer new antibodies to combat influenza and other infectious diseases, and where he sees the future of this exciting company. (Full disclosure: my venture firm Lux Capital is an equity investor in Visterra).
Share this Article
Recommended